Orchid Pharma Ltd - 524372 - Compliances-Reg.24(A)-Annual Secretarial Compliance
Annual Secretarial Compliance Report of the Company for the Financial Year ended on March 31, 2024.30-05-2024
30-05-2024
Orchid Pharma Ltd - 524372 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Transcript for the Investor/Analysts Earnings Call held on May 24, 2024.29-05-2024
Orchid Pharma Q4 Results Review - Foray Into Branded Formulations: Systematix
Enmetazobactam launch in Europe and U.S. is expected from Q2 FY25.28-05-2024
Orchid Pharma Ltd - 524372 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Find enclosed the copy of newspaper publication made on May 25, 2024 for financial results for the quarter and year ended on March 31, 2024.25-05-2024
Orchid Pharma Ltd - 524372 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Audio Recording of the Analysts/Investors Earnings Call held today i.e. May 24, 2024 at 04:00 P.M. (IST) to discuss the Audited Financial Results (Standalone and Consolidated) for the quarter and financial year ended on March 31, 2024.24-05-2024
FY24 Annual Result Announced for Orchid Pharma Ltd.
Pharmaceuticals company Orchid Pharma announced FY24 results: Sales for FY24 were at Rs 819.4 crore, up by 23% YoY. PAT surged 71.60% YoY to Rs 94.7 crore in FY24. A highlight of this quarter has been the progress of Orchid Pharma’s novel drug Enmetazobactam. Speaking on the Q4 results, Manish Dhanuka, Managing Director, Orchid Pharma said, “Our revenues have experienced a significant increase over the past year. We have concentrated on maximizing capacity utilization while maintaining stringent cost controls. The positive outcomes of these initiatives, combined with a robust product pipeline and Capex of more than Rs 800 Crore over the next few years, indicate promising future prospects.” Result PDF24-05-2024
Orchid Pharma Ltd - 524372 - Announcement under Regulation 30 (LODR)-Change in Directorate
Appointment of additional Director in the category of Non Executive Independent Director23-05-2024
Orchid Pharma Ltd - 524372 - Announcement under Regulation 30 (LODR)-Investor Presentation
Investor Presentation for Q4- Financial Year 2023-2423-05-2024
Orchid Pharma Ltd - 524372 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Press Release- Titled as "Orchid Pharma announces Q4 Results with 71.60% growth in Annual PAT"23-05-2024
Orchid Pharma Ltd - 524372 - STATEMENT ON DEVIATION OR VARIATION FOR PROCEEDS OF QUALIFIED INSTITUTIONS PLACEMENT FOR QUARTER ENDED MARCH 31, 2024
Statement on Nil Deviation or Variation for proceeds of Qualified Institutions Placement for Quarter ended March 31, 202423-05-2024